Hua Guo

机构：Shanxi Medical University, Nantong University, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Tianjin Medical University Cancer Institute and Hospital, Wuhan University, Affiliated Hospital of Nantong University, National Clinical Research, Fifth Hospital In Wuhan, Second Hospital of Shanxi Medical University, China Ocean Shipping (China), Molecular Oncology (United States), First Hospital of Xi'an, State Key Laboratory of Molecular Oncology · ORCID：0000-0002-3345-8005

发表论文 215 篇 · 总被引 6353 次 · h-index 43

代表论文

• PD-L1 induces autophagy and primary resistance to EGFR–TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway (2024 · Cell Death and Disease · 被引 38)
• Tertiary lymphoid structures as a potential prognostic biomarker for combined hepatocellular–cholangiocarcinoma (2024 · Hepatology International · 被引 20)
• Inhibition of Wnt/β-catenin increases anti-tumor activity by synergizing with sorafenib in hepatocellular carcinoma (2025 · Cell Death and Disease · 被引 13)
• Iron–Doxorubicin Hyaluronan Nanogel as an Effective Targeted Chemotherapy with Modulated Cardiotoxicity (2025 · Biomacromolecules · 被引 10)
• CCDC34 maintains stemness phenotype through β-catenin-mediated autophagy and promotes EGFR-TKI resistance in lung adenocarcinoma (2024 · Cancer Gene Therapy · 被引 9)
• Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer (2024 · Frontiers in Pharmacology · 被引 9)